Palbociclib in patients with non–small-cell lung cancer with cdkn2a alterations: results from the targeted agent and profiling utilization registry study

Eugene R. Ahn, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Elie G. Dib, Daniel E. Haggstrom, Kathryn B. Alguire, Carmen J. Calfa, Timothy L. Cannon, Pamela A. Crilley, Anu G. Gaba, Alissa S. Marr, Ashish Sangal, Ramya Thota, Kaitlyn R. Antonelli, Samiha Islam, Andrew L. Rygiel, Suanna S. Bruinooge, Richard L. Schilsky

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are reported. METHODS Eligible patients were ≥ 18 years old with advanced NSCLC, no remaining standard treatment options, measurable disease, Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate organ function. Patients with NSCLC with CDKN2A alterations and no Rb mutations received palbociclib 125 mg orally once daily for 21 days, followed by 7 days off. Simon’s two-stage design was used with a primary study end point of objective response or stable disease (SD) of at least 16 weeks in duration. Secondary end points are progression-free survival (PFS), overall survival (OS), and safety. RESULTS Twenty-nine patients were enrolled from January 2017 to June 2018; two patients were not evaluable for response but were included in safety analyses. One patient with partial response and six patients with SD were observed, for a disease control rate of 31% (90% CI, 19% to 40%). Median PFS was 8.1 weeks (95% CI, 7.1 to 16.0 weeks), and median OS was 21.6 weeks (95% CI, 14.1 to 41.1 weeks). Eleven patients had at least 1 grade 3 or 4 adverse event (AE) or serious AE (SAE) possibly related to palbociclib (most common, cytopenias). Other AEs or SAEs possibly related to the treatment included anorexia, fatigue, febrile neutropenia, hypophosphatemia, sepsis, and vomiting. CONCLUSION Palbociclib monotherapy demonstrated evidence of modest antitumor activity in heavily pretreated patients with NSCLC with CDKN2A alterations. Additional investigation is necessary to confirm efficacy and utility of palbociclib in this population.

Original languageEnglish (US)
Pages (from-to)757-766
Number of pages10
JournalJCO Precision Oncology
StatePublished - 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Palbociclib in patients with non–small-cell lung cancer with cdkn2a alterations: results from the targeted agent and profiling utilization registry study'. Together they form a unique fingerprint.

Cite this